Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)

NCT04248452 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04248452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04248452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 26, 2020
Completion date
March 31, 2028
Enrollment
314 (estimated)
Sites
453

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iva esophageal adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage ivb esophageal adenocarcinoma ajcc v8, clinical stage ivb gastric cancer ajcc v8, metastatic esophageal adenocarcinoma, metastatic gastric adenocarcinoma, oligometastatic esophageal adenocarcinoma, oligometastatic gastric adenocarcinoma, pathologic stage iv esophageal adenocarcinoma ajcc v8, pathologic stage iv gastric cancer ajcc v8, pathologic stage iva esophageal adenocarcinoma ajcc v8, pathologic stage ivb esophageal adenocarcinoma ajcc v8